BINEX Co., Ltd.

Equities

A053030

KR7053030003

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
13,490 KRW -0.74% Intraday chart for BINEX Co., Ltd. -3.37% +50.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BINEX Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System MT
Sinjia Land Terminates Loan Deal With BINEX; Shares Up 6% MT
Sinjia Land Scraps Deal to Buy Alternative Fuels Firm Over Unmet Closing Condition MT
BINEX Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sinjia Land Extends Long Stop Date to Acquire BINEX Singapore MT
Sinjia Land Uses Portion of Proceeds from Share Placement for Deposit Payment to BINEX MT
Singapore Shares End Week on High Note; Del Monte Pacific Shares Zoom 4% on Higher Fiscal Q4 Profit MT
Sinjia Land to Make Refundable Deposit to BINEX in Relation to RTO Deal MT
Sinjia Land to Acquire BINEX Singapore in RTO Deal MT
With Investment Co., Ltd. acquired the remaining 16.63% stake in Rhinos Asset Management Co., Ltd from BINEX Co., Ltd.. CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month RE
Tranche Update on BINEX Co., Ltd.'s Equity Buyback Plan announced on August 23, 2021. CI
BINEX Co., Ltd.'s Equity Buyback announced on August 23, 2021, has closed with 283,286 shares, representing 0.91% for KRW 5,532.99 million. CI
BINEX Co., Ltd. announces an Equity Buyback for 283,286 shares. CI
BINEX Co., Ltd. authorizes a Buyback Plan. CI
An unknown buyer cancelled the acquisition of 6.97% stake in PeproMene Bio. Inc. from BINEX Co., Ltd.. CI
Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd. CI
Noile-Immune Biotech Inc announced that it has received ¥999.998803 million in funding from BINEX Co., Ltd. CI
BINEX Co., Ltd. announced that it has received KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc. CI
BINEX Co., Ltd. announced that it expects to receive KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc. CI
PharmAbcine Signs CMO Contract with Binex CI
PharmAbcine Signs Long-Term Contract Manufacturing Organization Agreement for Olinvacimab with Binex CI
Genexine : South Korea's Genexine begins human trial of coronavirus vaccine RE
Chart BINEX Co., Ltd.
More charts
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A053030 Stock
  4. News BINEX Co., Ltd.
  5. Sinjia Land Terminates Loan Deal With BINEX; Shares Up 6%